In recent years, an increasing number of HDAC inhibitors have appeared and served as potential drugs for patients with HCC, such as resminostat, quisinostat, entinostat, and valproic acid [10,23–25]. The gene discussed is HDAC9; the disease is hepatocellular carcinoma.